Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial

Open access
Senti, G., Johansen, P., Haug, S., Bull, C., Gottschaller, C., Müller, P., Pfister, T., Maurer, P., Bachmann, M. F., Graf, N., Kündig, T. M. · 2009 · Clinical & Experimental Allergy

Abstract

Summary: Background B‐type CpG oligodeoxynucleotides (ODN) is currently used in clinical trials because of its prolonged half–life, which is due to its phosphorothioate backbone. A‐type CpG ODN is a stronger inducer of IFN but has an unstable phosphodiester backbone that has so far prohibited its clinical use. However, upon association with virus‐like particles (VLP) consisting of the bacteriophage Qβ coat protein, A‐type CpG ODN can be stabilized and can become an efficient adjuvant in mice. Therefore, the phase I/IIa study presented represents the first test of A‐type CpGs in humans. Objective To test the safety, tolerability and clinical efficacy of QbG10 as an adjuvant for subcutaneous immunotherapy with a house dust mite (HDM) allergen extract in allergic patients. Methods A single centre, open‐label phase I/IIa study evaluated the safety, tolerability and clinical efficacy of QbG10 as an adjuvant to immunotherapy with a subcutaneous HMD allergen extract in 20 patients suffering from HDM allergy. Twenty‐one patients were enrolled between March and July 2005. Individual immunotherapy lasted 10 weeks. Clinical end‐points included questionnaires, conjunctival provocation, skin prick tests and the measurement of allergen‐specific IgG and IgE. Results QbG10 was well tolerated. Almost complete tolerance to the allergen was observed in conjunctival provocation testing after treatment with QbG10, and symptoms of rhinitis and allergic asthma were significantly reduced. Within 10 weeks of therapy, patients were nearly symptom‐free and this amelioration lasted for at least 38 weeks post‐treatment. Following injections of QbG10 and HDM allergen extract, allergen‐specific IgG increased, while there was a transient increase in allergen‐specific IgE titres. Skin reactivity to HDM was reduced. Conclusion The subcutaneous application of HDM allergen, together with A‐type CpG ODN packaged into VLP, was safe. All patients achieved practically complete alleviation of allergy symptoms after 10 weeks of immunotherapy. This promising clinical outcome calls for larger placebo‐controlled phase II studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2008.03191.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 219

Metadata

Authors
Senti, G., Johansen, P., Haug, S., Bull, C., Gottschaller, C., Müller, P., Pfister, T., Maurer, P., Bachmann, M. F., Graf, N., & Kündig, T. M.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2009-03-12
Volume
39
Issue
4
Pages
562-570
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W1969251366
Cited by
219
References
2
FWCI
10.07
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial. https://app.cochat.ai/papers/10.1111/j.1365-2222.2008.03191.x
The paper
Senti, G., Johansen, P., Haug, S., Bull, C., Gottschaller, C., Müller, P., Pfister, T., Maurer, P., Bachmann, M. F., Graf, N., & Kündig, T. M. (2009). Use of A‐type CpG oligodeoxynucleotides as an adjuvant in allergen‐specific immunotherapy in humans: a phase I/IIa clinical trial. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2008.03191.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.